Pete McCabe

that allow organizations in a very limited and very controlled and defined way to access or retrieve data for purposes of advancing care.

Yes, absolutely.

And again, in two different ways.

One of the things that we spend a lot of time on

is the de-identified space where maybe COVID-19 is a great example.

Early on in COVID-19, a bunch of different organizations, including the government said, hey, we need to get access to this data if we're gonna be able to put a dent in this pandemic.

but it's all fragmented, right?

Can you help us?

And so quickly, 20 odd different leading institutions said, hey, we'll contribute our data.

If you guys can de-identify it, if you guys can tokenize it, we can make it available to researchers to go solve anything from the effectiveness of a new drug

to correlations on demographics and pre-existing conditions with incubation.

The FDA is quite supportive of reducing the amount of time and cost to develop new drugs.

We save millions lives and increase the livelihood of tens of millions in doing that.

One of the things that they've introduced is this concept called real world evidence.

real-world evidence sits on top of real-world data.

So think medical records that show that a drug might be efficacious for a disease it currently doesn't have an indication for.

You can take that to the FDA, wrap it with your other research, and rapidly reduce the cycle times and cost to develop new drugs and get treatments in the right hand.

And I would say

We're in the first inning.

We're not even 10 pitches into the first inning on what's possible in life sciences with real-world evidence and real-world data.